Y-mAbs Therapeutics IncNASDAQ:YMAB
- LAST PRICE11.9800
- TODAY'S CHANGE (%)-0.3300 (-2.6807%)
- Bid / Lots11.9100/ 1
- Ask / Lots16.2100/ 2
- Open / Previous Close12.2000 / 12.3100
- Day Range
- 52 Week Range
- Volume242,420
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | YMAB |
|---|---|---|
| 09:32 ET | 1496 | 12.2 |
| 09:34 ET | 465 | 12.19 |
| 09:38 ET | 100 | 12.11 |
| 09:41 ET | 1175 | 12.215 |
| 09:45 ET | 100 | 12.22 |
| 09:48 ET | 100 | 12.22 |
| 09:50 ET | 100 | 12.235 |
| 09:52 ET | 892 | 12.36 |
| 09:56 ET | 300 | 12.3 |
| 09:57 ET | 100 | 12.275 |
| 10:06 ET | 200 | 12.24 |
| 10:08 ET | 100 | 12.25 |
| 10:10 ET | 213 | 12.25 |
| 10:17 ET | 528 | 12.245 |
| 10:24 ET | 1414 | 12.31 |
| 10:30 ET | 100 | 12.305 |
| 10:35 ET | 127 | 12.282 |
| 10:37 ET | 200 | 12.305 |
| 10:39 ET | 812 | 12.36 |
| 10:44 ET | 2096 | 12.47 |
| 10:51 ET | 152 | 12.475 |
| 10:53 ET | 400 | 12.4875 |
| 10:55 ET | 1333 | 12.54 |
| 11:02 ET | 2711 | 12.51 |
| 11:04 ET | 200 | 12.54 |
| 11:08 ET | 1100 | 12.52 |
| 11:11 ET | 1544 | 12.5 |
| 11:13 ET | 611 | 12.52 |
| 11:20 ET | 11897 | 12.48 |
| 11:22 ET | 6035 | 12.45 |
| 11:24 ET | 7102 | 12.45 |
| 11:26 ET | 666 | 12.51 |
| 11:29 ET | 1115 | 12.44 |
| 11:33 ET | 100 | 12.31 |
| 11:36 ET | 100 | 12.31 |
| 11:38 ET | 600 | 12.41 |
| 11:47 ET | 129 | 12.4 |
| 11:51 ET | 1098 | 12.375 |
| 12:00 ET | 500 | 12.39 |
| 12:05 ET | 100 | 12.365 |
| 12:07 ET | 100 | 12.32 |
| 12:09 ET | 200 | 12.33 |
| 12:18 ET | 100 | 12.3 |
| 12:21 ET | 600 | 12.3 |
| 12:32 ET | 100 | 12.27 |
| 12:38 ET | 700 | 12.24 |
| 12:39 ET | 500 | 12.25 |
| 12:41 ET | 100 | 12.24 |
| 12:43 ET | 444 | 12.235 |
| 12:50 ET | 1446 | 12.2 |
| 12:52 ET | 600 | 12.2 |
| 12:56 ET | 700 | 12.285 |
| 12:57 ET | 100 | 12.285 |
| 12:59 ET | 800 | 12.3 |
| 01:01 ET | 601 | 12.355 |
| 01:03 ET | 100 | 12.34 |
| 01:06 ET | 200 | 12.34 |
| 01:08 ET | 200 | 12.34 |
| 01:10 ET | 500 | 12.34 |
| 01:12 ET | 200 | 12.31 |
| 01:14 ET | 100 | 12.345 |
| 01:15 ET | 100 | 12.335 |
| 01:17 ET | 666 | 12.39 |
| 01:19 ET | 100 | 12.41 |
| 01:21 ET | 115 | 12.43 |
| 01:26 ET | 300 | 12.44 |
| 01:28 ET | 100 | 12.44 |
| 01:30 ET | 1100 | 12.365 |
| 01:44 ET | 500 | 12.315 |
| 01:50 ET | 2919 | 12.27 |
| 01:51 ET | 2613 | 12.09 |
| 01:55 ET | 2025 | 12.075 |
| 01:57 ET | 400 | 12.045 |
| 02:00 ET | 100 | 12.01 |
| 02:02 ET | 372 | 11.9 |
| 02:04 ET | 900 | 11.94 |
| 02:06 ET | 200 | 11.93 |
| 02:08 ET | 300 | 11.94 |
| 02:09 ET | 2300 | 11.93 |
| 02:11 ET | 1080 | 11.9 |
| 02:13 ET | 800 | 11.89 |
| 02:15 ET | 992 | 11.87 |
| 02:18 ET | 200 | 11.83 |
| 02:20 ET | 100 | 11.82 |
| 02:22 ET | 1955 | 11.845 |
| 02:24 ET | 320 | 11.845 |
| 02:26 ET | 1300 | 11.91 |
| 02:29 ET | 700 | 11.9307 |
| 02:31 ET | 1968 | 11.97 |
| 02:33 ET | 600 | 11.97 |
| 02:36 ET | 224 | 11.97 |
| 02:40 ET | 100 | 11.98 |
| 02:42 ET | 3816 | 12 |
| 02:44 ET | 1900 | 12.07 |
| 02:45 ET | 600 | 12.04 |
| 02:49 ET | 2880 | 12 |
| 02:51 ET | 2584 | 11.965 |
| 02:54 ET | 300 | 11.97 |
| 02:56 ET | 505 | 11.98 |
| 02:58 ET | 200 | 12 |
| 03:00 ET | 400 | 11.98 |
| 03:02 ET | 540 | 11.99 |
| 03:03 ET | 600 | 12 |
| 03:05 ET | 3006 | 12.13 |
| 03:07 ET | 500 | 12.055 |
| 03:09 ET | 237 | 12.031 |
| 03:12 ET | 525 | 12.03 |
| 03:16 ET | 3772 | 12 |
| 03:18 ET | 676 | 11.995 |
| 03:20 ET | 1703 | 12.035 |
| 03:25 ET | 2700 | 12.02 |
| 03:27 ET | 100 | 12.035 |
| 03:30 ET | 500 | 12.055 |
| 03:32 ET | 929 | 12.08 |
| 03:34 ET | 206 | 12.065 |
| 03:36 ET | 200 | 12.07 |
| 03:38 ET | 100 | 12.07 |
| 03:39 ET | 1301 | 12.08 |
| 03:41 ET | 4155 | 12 |
| 03:43 ET | 2084 | 11.995 |
| 03:45 ET | 2904 | 11.975 |
| 03:48 ET | 2246 | 11.98 |
| 03:50 ET | 742 | 12 |
| 03:52 ET | 1500 | 12.01 |
| 03:54 ET | 2507 | 11.99 |
| 03:56 ET | 11142 | 11.99 |
| 03:57 ET | 4906 | 11.99 |
| 03:59 ET | 11203 | 11.98 |
Jun 7, 2024
Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting, from 7:05AM ET on Friday Jun 07, 2024 by Dow Jones
7:05AM ET on Friday Jun 07, 2024 by Dow Jones
Jun 5, 2024
Press Release: Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer, from 7:05AM ET on Wednesday Jun 05, 2024 by Dow Jones
7:05AM ET on Wednesday Jun 05, 2024 by Dow JonesY-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer, from 7:05AM ET on Wednesday Jun 05, 2024 by Dow Jones
7:05AM ET on Wednesday Jun 05, 2024 by Dow Jones
Jun 1, 2024
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting, from 8:15AM ET on Saturday Jun 01, 2024 by Dow Jones
8:15AM ET on Saturday Jun 01, 2024 by Dow JonesY-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting, from 8:05AM ET on Saturday Jun 01, 2024 by Dow Jones
8:05AM ET on Saturday Jun 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Y-mAbs Therapeutics Inc | 558.6M | -24.2x | --- |
Urogen Pharma Ltd | 491.0M | -3.9x | --- |
SAGE Therapeutics Inc | 660.2M | -1.3x | --- |
Zymeworks Inc | 630.7M | -5.1x | --- |
Editas Medicine Inc | 460.5M | -2.5x | --- |
Alector Inc | 462.6M | -3.1x | --- |
Company Information
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Contact Information
- Headquarters
- 230 PARK AVENUE, SUITE 3350NEW YORK, NY, United States 10169
- Phone
- 212-847-9841
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- James Healy
- President, Chief Executive Officer, Director
- Michael Rossi
- Vice Chairman of the Board, Chief Business Officer
- Thomas Gad
- Chief Financial Officer, Executive Vice President, Treasurer, Secretary
- Bo Kruse
- Chief Operating Officer, Senior Vice President
- Joris Wilms
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $558.6M |
|---|---|
Revenue (TTM) | $84.5M |
Shares Outstanding | 43.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.66 |
EPS | $-0.50 |
Book Value | $2.31 |
P/E Ratio | -24.2x |
Price/Sales (TTM) | 6.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -29.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
